Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
— EPICOfficial title:
The Expanding Paramedicine in the Community (Study)
NCT number | NCT02034045 |
Other study ID # | EPIC - RCT |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2013 |
Est. completion date | December 2015 |
Verified date | April 2019 |
Source | St. Michael's Hospital, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Initiatives aimed at reducing Emergency Department (ED) wait times and improved community
health initiatives are major priorities in Canada. Three of the most common chronic diseases
worldwide are Diabetes Mellitus (DM), Congestive Heart Failure (CHF) and Chronic Obstructive
Pulmonary Disease (COPD). These diseases are on the rise and currently cost the Canadian
health care system billions of dollars every year including the cost of hospitalizations and
ED visits. The existing health care system does not have the resources and manpower to
effectively care for these patients in the future.
Paramedics are currently employed to provide Emergency Medical Services in remote, rural and
urban settings in Canada.
They are highly trained health care practitioners that are mobile in the community and
currently work in a physician medically delegated act model and therefore are positioned to
take on new collaborative roles to deliver patient care in the community setting. Increased
community paramedic care could decrease the utilization of the health care system resources
for patients with chronic disease. Using a randomized control trial design we will attempt to
answer the question of whether whether non-emergency community paramedics conducting home
visits to undertake assessments and evidence-based treatments of patients in partnership with
family doctors will decrease the rate of patient hospitalization.
Status | Completed |
Enrollment | 467 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Residents of the region of York, Ontario, 18 years of age or older, diagnosed at any point in time with COPD, CHF, or DM and identified by the Family Health Care Team as high risk for admission. Exclusion Criteria: Residents of long-term care facilities or if have cognitive impairment, uncontrolled psychiatric disease or language barriers that would make it difficult to understand the consent and communicate with the paramedic during the scheduled visits, unless the individual with power of attorney for personal care consented and agreed to be at each visit. |
Country | Name | City | State |
---|---|---|---|
Canada | Health for All and Markham Family Health Team | Markham | Ontario |
Canada | Aurora-Newmarket Family Health Team | Newmarket | Ontario |
Canada | Owen Sound Family Health Team | Owen Sound | Ontario |
Canada | Stouffville Medical Centre | Stouffville | Ontario |
Lead Sponsor | Collaborator |
---|---|
St. Michael's Hospital, Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Trial Fidelity and Safety | Measures of intervention compliance and safety (ie. Completed assessments and visits, protocol violations identified by physician review of EMR) | maximum 2 years | |
Primary | Hospital admissions per patient | The primary outcome of this trial is the one-year measurement of hospital admissions per patient. | maximum 2 years | |
Secondary | Health Resource Utilization | The secondary outcomes will be measures of health system utilization at one year (reported as all cause and disease specific) and will include: Calls to 911 (regardless of whether patient was transported to hospital) Visits to the participating Family Health Team clinics and any after-hours clinics Length of stay in hospital |
maximum 2 years | |
Secondary | Cost Effectiveness | Cost effectiveness analysis for this model of care based on the composite outcome measures. | maximum 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |